Magnesium lithospermate B loaded PEGylated solid lipid nanoparticles for improved oral bioavailability

Area of Science:

• Nanotechnology
• Pharmacology
• Drug Delivery

Background:

• Magnesium lithospermate B (MLB) is a polyphenol with therapeutic potential but suffers from poor oral bioavailability.
• Effective oral delivery systems are needed to harness the pharmacological activities of MLB.

Purpose of the Study:

• To develop and characterize polyethylene glycol monostearate (PEG-SA) modified solid lipid nanoparticles (SLNs) for enhanced oral delivery of MLB.
• To evaluate the bioavailability and cellular transport mechanisms of MLB-loaded SLNs.

Main Methods:

• MLB-loaded SLNs were prepared using the solvent diffusion method.
• SLNs were surface-modified with PEG-SA.
• Particle size, drug loading, pharmacokinetic studies in rats, and cell permeability assays using MDCK cells were performed.

Main Results:

• PEG-SA modification resulted in smaller particle sizes (53.50nm) and increased drug loading capacity (up to 16.18%).
• Pharmacokinetic studies showed significantly higher Cmax and AUC for MLB-SLNs compared to MLB solution.
• Relative oral bioavailability of PEG-SA modified MLB-SLNs reached 753.98% compared to intravenous administration, with enhanced permeability and cellular uptake in MDCK cells.

Conclusions:

• PEG-SA modified SLNs represent a promising strategy for improving the oral bioavailability of Magnesium lithospermate B.
• The enhanced cellular transport and permeability contribute to the improved oral delivery of MLB via this nanocarrier system.